Delayed administration of VEGF rescues spinal motor neurons from death with a a short effective time frame in excitotoxic experimental models in vivo

ASN Neuro

Volumn 4, Issue 2, 2012, Pages 121-129

  Tovar y Romo, Luis B ^a,b   Tapia, Ricardo ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c NONE

Author keywords

Amyotrophic lateral sclerosis; Neurodegeneration; Neuroprotection; Rat; Spinal cord

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT VASCULOTROPIN; AMINO ACID RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINE ACETYLTRANSFERASE; GLIAL FIBRILLARY ACIDIC PROTEIN; VASCULOTROPIN A;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; EXCITOTOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICRODIALYSIS; MOTONEURON; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OSMOTIC PUMP; PARALYSIS; RAT; SPINAL CORD NERVE CELL; SYMPTOMATOLOGY; THERAPY DELAY; ANALYSIS OF VARIANCE; ANIMAL; CELL DEATH; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY; SPINAL CORD DISEASE; TIME; WISTAR RAT;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANALYSIS OF VARIANCE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; CHOLINE O-ACETYLTRANSFERASE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID AGONISTS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICRODIALYSIS; MOTOR ACTIVITY; MOTOR NEURONS; NERVE DEGENERATION; PARALYSIS; RATS; RATS, WISTAR; SPINAL CORD DISEASES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859032386     PISSN: None     EISSN: 17590914     Source Type: Journal    
DOI: 10.1042/AN20110057     Document Type: Article

References (41)

1. ALS CNTF Treatment Study Group (1996) A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46:1244-1249.
2. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429:413-417.
3. Bedlack RS (2010) Amyotrophic lateral sclerosis: current practice and future treatments. Curr Opin Neurol 23:524-529.
4. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, Braga M, Silani V, De Biasi S (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci 191:25-33.
5. Bogaert E, d'Ydewalle C, Van Den Bosch L (2010) Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target. CNS Neurol Disord Drug Targets 9:297-304.
6. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JH, Dobbins T (1998) A placebo-controlled trial of insulinlike growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51:583-586.
7. Brockington A, Wharton SB, Fernando M, Gelsthorpe CH, Baxter L, Ince PG, Lewis CE, Shaw PJ (2006) Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65:26-36.
8. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18:327-338.
9. Corona JC, Tapia R (2004) AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo. J Neurochem 89:988-997.
10. Corona JC, Tapia R (2007) Ca2+-permeable AMPA receptors and intracellular Ca2+ determine motoneuron vulnerability in rat spinal cord in vivo. Neuropharmacology 52:1219-1228.
11. Corona JC, Tapia R (2008) Calpain inhibition protects spinal motoneurons from the excitotoxic effects of AMPA in vivo. Neurochem Res 33:1428-1434.
12. Corona JC, Tovar-y-Romo LB, Tapia R (2007) Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis. Expert Opin Ther Targets 11:1415-1428.
13. Dal Canto MC, Gurney ME (1995) Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 676:25-40.
14. Dodge JC, Haidet AM, Yang W, Passini MA, Hester M, Clarke J, Roskelley EM, Treleaven CM, Rizo L, Martin H, Kim SH, Kaspar R, Taksir TV, Griffiths DA, Cheng SH, Shihabuddin LS, Kaspar BK (2008) Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 16:1056-1064.
15. Fryer HJ, Wolf DH, Knox RJ, Strittmatter SM, Pennica D, O'Leary RM, Russell DS, Kalb RG (2000) Brain-derived neurotrophic factor induces excitotoxic sensitivity in cultured embryonic rat spinal motor neurons through activation of the phosphatidylinositol 3-kinase pathway. J Neurochem 74:582-595.
16. Grosskreutz J, Van Den Bosch L, Keller BU (2010) Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 47:165-174.
17. Ilieva H, Polymenidou M, Cleveland DW (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187:761-772.
18. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839-842.
19. Kim SH, Won SJ, Sohn S, Kwon HJ, Lee JY, Park JH, Gwag BJ (2002) Brainderived neurotrophic factor can act as a pronecrotic factor through transcriptional and translational activation of NADPH oxidase. J Cell Biol 159:821-831.
20. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebocontrolled study. The North America ALS/IGF-I Study Group. Neurology 49:1621-1630.
21. Li B, Xu W, Luo C, Gozal D, Liu R (2003) VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res 111:155-164.
22. Lunn JS, Sakowski SA, Kim B, Rosenberg AA, Feldman EL (2009) Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev Neurobiol 69:871-884.
23. Morrison BM, Janssen WG, Gordon JW, Morrison JH (1998) Time course of neuropathology in the spinal cord of G86R superoxide dismutase transgenic mice. J Comp Neurol 391:64-77.
24. Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, Yokoyama M, Moritaz K, Shoji M, Abe K (2005) Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 27:768-772.
25. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131-138.
26. Pradat PF, Dib M (2009) Biomarkers in amyotrophic lateral sclerosis: facts and future horizons. Mol Diagn Ther 13:115-125.
27. Shook SJ, Pioro EP (2009) Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Ann Neurol 65(Suppl. 1):S10-S16.
28. Siciliano G, Carlesi C, Pasquali L, Piazza S, Pietracupa S, Fornai F, Ruggieri S, Murri L (2010) Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets 9:305-313.
29. Stephens B, Guiloff RJ, Navarrete R, Newman P, Nikhar N, Lewis P (2006) Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A morphometric study. J Neurol Sci 244:41-58.
30. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, Van Damme P, Rutten B, Man WY, De Mol M, Wyns S, Manka D, Vermeulen K, VAN Den Bosch L, Mertens N, Schmitz C, Robberecht W, Conway EM, Collen D, Moons L, Carmeliet P (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8:85-92.
31. Suzuki M, Svendsen CN (2008) Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 31:192-198.
32. The BDNF Study Group(1999) A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52:1427-1433.
33. Tolosa L, Mir M, Asensio VJ, Olmos G, Llado J (2008) Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase. J Neurochem 105:1080-1090.
34. Tovar-y-Romo LB, Tapia R (2006) Cerebral neurons of transgenic ALS mice are vulnerable to glutamate release stimulation but not to increased extracellular glutamate due to transport blockade. Exp Neurol 199:281-290.
35. Tovar-y-Romo LB, Tapia R (2010) VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK. J Neurochem 115:1090-1101.
36. Tovar-y-Romo LB, Zepeda A, Tapia R (2007) Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration. J Neuropathol Exp Neurol 66:913-922.
37. Tovar-y-Romo LB, Santa-Cruz LD, Tapia R (2009a) Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis. Mol Neurodegener 4:31.
38. Tovar-y-Romo LB, Santa-Cruz LD, Zepeda A, Tapia R (2009b) Chronic elevation of extracellular glutamate due to transport blockade is innocuous for spinal motoneurons in vivo. Neurochem Int 54:186-191.
39. Van Den Bosch L, Storkebaum E, Vleminckx V, Moons L, Vanopdenbosch L, Scheveneels W, Carmeliet P, Robberecht W (2004) Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol Dis 17:21-28.
40. Wu DC, Re DB, Nagai M, Ischiropoulos H, Przedborski S (2006) The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci USA 103:12132-12137.
41. Zheng C, Nennesmo I, Fadeel B, Henter JI (2004) Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 56:564-567.